Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced that on December 15, 2025 its Compensation Committee granted 24,500 stock options and 2,000 restricted stock units (RSUs) to new non-executive employees as inducement awards approved under Nasdaq Listing Rule 5635(c)(4).

The awards are governed by the Amended and Restated 2021 Equity Inducement Plan. Vesting for the stock options is 25% at one year then monthly to the fourth anniversary; RSU vesting is 25% at one year then annually to the fourth anniversary, each subject to continued service.

Argus Dec 17 session

-6.93% close to close Open Argus

Details

News Market Reaction – STRO

In the Dec 17 session, STRO declined 6.93%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.9% in the session following this news. A negative reaction despite the routine na...

Analysis

The stock moved -6.9% in the session following this news. A negative reaction despite the routine nature of these inducement grants would fit a pattern where even neutral or operational updates sometimes coincided with downside, such as the -12.82% move around the reverse split. The grants add modest equity over four years but occur alongside a Q3 net loss of $56.9M and substantial restructuring charges of $49.0M year‑to‑date, which may keep risk perceptions elevated.

Key Figures

Stock options granted: 24,500 shares RSUs granted: 2,000 RSUs Q3 2025 revenue: $9.7M +5 more

Stock options granted

24,500 shares

Inducement grants to new non‑executive employees under 2021 Equity Inducement Plan

RSUs granted

2,000 RSUs

Inducement grants vesting over four years subject to continued service

Q3 2025 revenue

$9.7M

Quarterly revenue, up from $8.5M a year ago

Q3 2025 net loss

$56.9M

Quarterly net loss, larger than $48.8M a year ago

Restructuring charges Q3

$9.6M

Restructuring costs recorded in Q3 2025

Restructuring charges YTD

$49.0M

Year‑to‑date restructuring charges in 2025

Cash & securities

$167.6M

Unrestricted cash, cash equivalents and marketable securities as of Sep 30, 2025

Nine‑month revenue 2025

$90.8M

Revenue for nine months 2025 vs $47.2M prior year period

Historical Context

5 past events · Latest: Dec 03

5 events

1. Dec 03

   Clinical trial start

   24h Move

   +19.2%

   First cohort dosed in Phase 1 STRO‑004 trial in TF‑expressing tumors.

2. Dec 01

   Reverse stock split

   24h Move

   -12.8%

   1‑for‑10 reverse split to regain compliance with Nasdaq bid price rule.

3. Nov 12

   R&D day update

   24h Move

   -0.3%

   Virtual R&D Day outlining ADC platform, STRO‑004 progress, and pipeline plans.

4. Nov 06

   Earnings and pipeline

   24h Move

   -4.3%

   Q3 2025 results, STRO‑004 IND clearance, and cash runway into at least mid‑2027.

5. Nov 05

   Conference announcement

   24h Move

   -3.5%

   Announcement of virtual R&D Day focused on ADC innovation and pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

Nasdaq Listing Rule 5635(c)(4), restricted stock units (RSUs), antibody drug conjugates (ADCs), Equity Inducement Plan

4 terms

Nasdaq Listing Rule 5635(c)(4) regulatory

"approved by the Compensation Committee ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units (RSUs) financial

"granted stock options to purchase 24,500 shares ... and 2,000 restricted stock units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

antibody drug conjugates (ADCs) medical

"pioneering site-specific and novel-format antibody drug conjugates (ADCs)"

Antibody drug conjugates (ADCs) are specialized medicines that combine a targeted antibody with a powerful drug, designed to attack specific disease cells while minimizing harm to healthy ones. This approach allows for more precise treatment, often leading to better outcomes. For investors, ADCs represent innovative therapies with the potential for significant market impact and growth in the healthcare sector.

Equity Inducement Plan financial

"subject to the terms and conditions of Sutro’s Amended and Restated 2021 Equity Inducement Plan."

An equity inducement plan is a program that gives new hires or targeted employees stock, restricted shares, or stock options as a hiring or retention reward, often separate from the company’s regular long-term incentive plans. Think of it as a signing bonus paid in company stock: it helps attract and keep talent but matters to investors because it can dilute existing shares, change executive incentives, and affect future earnings through compensation expense.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the Compensation Committee of Sutro’s Board of Directors granted stock options to purchase 24,500 shares of Sutro common stock and 2,000 restricted stock units (RSUs) to new non-executive employees. The grants were made as an inducement material to the employees’ acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options and RSUs are subject to the terms and conditions of Sutro’s Amended and Restated 2021 Equity Inducement Plan. One-fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee’s hire date and monthly thereafter until fully vested on the fourth anniversary, subject to the employee’s continued service with Sutro on each such vesting date. One-fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the employee’s hire date and annually thereafter until fully vested on the fourth anniversary, subject to the employee’s continued service with Sutro on each such vesting date.

About Sutro Biopharma

Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sutro Biopharma (STRO) announce on December 15, 2025?

Sutro granted 24,500 stock options and 2,000 RSUs to new non-executive employees as inducement awards approved under Nasdaq Rule 5635(c)(4).

How are the Sutro (STRO) stock options structured and when do they vest?

Options vest 25% after one year then monthly thereafter, fully vesting on the fourth anniversary, subject to continued service.

What is the RSU vesting schedule for the December 2025 Sutro (STRO) grants?

RSUs vest 25% after one year and then annually, fully vesting on the fourth anniversary, subject to continued service.

Under which plan were Sutro (STRO) inducement awards made?

The awards were granted under Sutro’s Amended and Restated 2021 Equity Inducement Plan.

Why were the stock option and RSU grants to new hires at Sutro (STRO) approved?

The Compensation Committee approved the grants as inducement material to the employees’ acceptance of employment and in accordance with Nasdaq Listing Rule 5635(c)(4).

Do the Sutro (STRO) inducement awards include executive-level employees?

The announcement specifies the grants were made to new non-executive employees.